Genmab A/S 2016 SR
The report outlines Genmab's commitment to improving patient lives through innovative antibody products and its 2025 vision for transforming cancer treatment. Key focus areas include employee well-being, ethics in clinical studies, environmental impact reduction, and business transparency. In 2016, the company achieved a 47% female representation at the director level and above, though it fell short of its 25% female board member target. The report also details the construction of a new R&D facility in Utrecht designed to meet BREEAM Excellent certification standards.
Company: Genmab A/S
Sector: Professional & technical services
Country: Denmark
Year: 2016
Type: SR
Pages: 9
Back to company
Genmab A/S
Corporate Social Responsibility Report
The report outlines Genmab's commitment to improving patient lives through innovative antibody products and its 2025 vision for transforming cancer treatment. Key focus areas include employee well-being, ethics in clinical studies, environmental impact reduction, and business transparency. In 2016, the company achieved a 47% female representation at the director level and above, though it fell short of its 25% female board member target. The report also details the construction of a new R&D facility in Utrecht designed to meet BREEAM Excellent certification standards.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees